These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34343945)

  • 1. Living Under Coronavirus and Injecting Drugs in Bristol (LUCID-B): A qualitative study of experiences of COVID-19 among people who inject drugs.
    Kesten JM; Holland A; Linton MJ; Family H; Scott J; Horwood J; Hickman M; Telfer M; Ayres R; Hussey D; Wilkinson J; Hines LA
    Int J Drug Policy; 2021 Dec; 98():103391. PubMed ID: 34343945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of the COVID-19 pandemic on people who inject drugs accessing harm reduction services in an rural American state.
    Thakarar K; Kohut M; Hutchinson R; Bell R; Loeb HE; Burris D; Fairfield KM
    Harm Reduct J; 2022 Jul; 19(1):80. PubMed ID: 35869523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives.
    May T; Dawes J; Fancourt D; Burton A
    Int J Drug Policy; 2022 Aug; 106():103752. PubMed ID: 35653821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How has the COVID-19 epidemic affected the risk behaviors of people who inject drugs in a city with high harm reduction service coverage in Vietnam? A qualitative investigation.
    Nguyen TT; Hoang GT; Nguyen DQ; Nguyen AH; Luong NA; Laureillard D; Nagot N; Des Jarlais D; Duong HT; Nham TTT; Khuat OTH; Pham KM; Le MS; Michel L; Rapoud D; Le GM
    Harm Reduct J; 2022 Jan; 19(1):6. PubMed ID: 35090482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study.
    Ude M; Behrends CN; Kelly S; Schackman BR; Clear A; Goldberg R; Gelberg K; Kapadia SN
    Harm Reduct J; 2023 Feb; 20(1):12. PubMed ID: 36732773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health service utilisation and access for people who inject drugs during COVID-19.
    Efunnuga H; Higgs P; Walker S; O'Keefe D
    Drug Alcohol Rev; 2022 Sep; 41(6):1304-1310. PubMed ID: 35266229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV Care Continuum Services for People Who Inject Drugs in Kazakhstan During COVID-19: A Qualitative Study of Service Provider Perspectives.
    McCrimmon T; Sundelson A; Darisheva M; Gilbert L; Hunt T; Terlikbayeva A; Primbetova S; El-Bassel N
    Glob Health Sci Pract; 2022 Apr; 10(2):. PubMed ID: 35487549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
    Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
    Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services.
    Croxford S; Emanuel E; Ibitoye A; Njoroge J; Edmundson C; Bardsley M; Heinsbroek E; Hope V; Phipps E
    Public Health; 2021 Mar; 192():8-11. PubMed ID: 33601307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia.
    Roxburgh A; Jauncey M; Day C; Bartlett M; Cogger S; Dietze P; Nielsen S; Latimer J; Clark N
    Harm Reduct J; 2021 Feb; 18(1):20. PubMed ID: 33596940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Maintaining HIV and HCV prevention and care for people who inject drugs despite COVID-19 in Hai Phong, Vietnam".
    Giang HT; Duc NQ; Molès JP; Vinh VH; Nagot N; Thanh NTT; Huong DT; Oanh KTH; Khue PM; Mai LS; Trang NT; Ngoc PT; Quillet C; Feelemyer J; Vallo R; Michel L; Jarlais DD; Laureillard D; Rapoud D
    Int J Drug Policy; 2022 Dec; 110():103870. PubMed ID: 36244242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia.
    Harris RE; Richardson J; Frasso R; Anderson ED
    Int J Drug Policy; 2018 Feb; 52():56-61. PubMed ID: 29241143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health literacy and changes in pattern of drug use among participants at the Stockholm Needle Exchange Program during the COVID-19 pandemic.
    Lindqvist K; Wallmofeldt C; Holmén E; Hammarberg A; Kåberg M
    Harm Reduct J; 2021 May; 18(1):52. PubMed ID: 33971892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substance use during the COVID-19 pandemic: What is really happening?
    Mellos E; Paparrigopoulos T
    Psychiatriki; 2022 Mar; 33(1):17-20. PubMed ID: 35255473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accessing needle exchange services in disasters for remote areas of Aotearoa New Zealand.
    Rijnink A; Blake D; Groot S; Brough C
    Harm Reduct J; 2022 Dec; 19(1):145. PubMed ID: 36544156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The experiences of people who inject drugs of skin and soft tissue infections and harm reduction: A qualitative study.
    Dunleavy K; Hope V; Roy K; Taylor A
    Int J Drug Policy; 2019 Mar; 65():65-72. PubMed ID: 30665085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives.
    Austin EJ; Corcorran MA; Briggs ES; Frost MC; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Jarlais DCD; Williams EC; Glick SN
    Int J Drug Policy; 2022 Nov; 109():103825. PubMed ID: 35977459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.